New drugs for BNCT: an experimental approach.
New kinds of boron-containing drugs were developed and tested in several murine tumor models. The boron-containing ether lipid B-Et-11-OMe was injected in mammary carcinoma (AT17) and osteosarcoma (OTS-64) bearing mice. Furthermore boron-substituted ferrocenium derivatives were tested. Two were excessively toxic; the third could be investigated. Boron accumulation and time-dependent biodistribution were determined using alpha-particle sensitive films and inductively coupled plasma-atomic emission pectrometry (ICP-AES) and -mass spectrometry (ICP-MS) of tumors, organs and tissues. Additionally, a new method of boron detection by NMR is in preparation.
Dept. of Radiation Oncology, Klinikum rechts der Isar, Munich, Germany. Lothar.Weissfloch@LRZ.TUM.de
L
L
Weissfloch
M
M
Bremer
P
P
Lemmen
T
T
Probst
M
M
Wagner
M
M
Peller
T
T
Auberger
R
R
Senekowitsch-Schmidtke
K
K
Tempel
M
M
Molls
D000818:Animals; D001880:Boranes / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D016754:Boron Neutron Capture Therapy / Q000379:methods*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D012516:Osteosarcoma / Q000532:radiotherapy*; D010713:Phosphatidylcholines / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D014018:Tissue Distribution
C087324:1-(9-o-carboranyl)nonyl-2-methyl-glycero-3-phosphocholine; D001880:Boranes; D010713:Phosphatidylcholines